Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, featuring one oral and two poster sessions. The data included findings for TNX-1700 and TNX-4700, underscoring the company's progress in developing cancer therapies.
For TNX-1700, the company reported results supporting its potential to reduce inflammation and tumor progression in gastric cancer models, as well as favorable pharmacokinetics. TNX-4700 demonstrated promising in vitro activity targeting BTLA (B- and T-lymphocyte attenuator), a checkpoint receptor, suggesting its potential as a cancer immunotherapy candidate either alone or in combination with other checkpoint inhibitors.
These findings are significant as they advance Tonix's pipeline in immuno-oncology, an area of high unmet medical need. The company is leveraging its expertise in immunology to develop novel treatments beyond its established CNS portfolio. Tonix is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments. Its recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years.
The company's CNS commercial infrastructure supports marketed products including Zembrace SymTouch and Tosymra for acute migraine. Tonix is also evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, its CNS pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease.
On the immunology side, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. The preclinical data presented at AACR 2026 highlight the company's diversification into oncology, potentially expanding its therapeutic reach.
For investors, these developments could signal growth opportunities as Tonix broadens its pipeline. However, it is important to note that product development candidates are investigational and have not been approved for any indication. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
